Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better?

Affiliations

¹ Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia sherene.loi@petermac.org.
² Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Editorial

Sherene Loi et al. J Clin Oncol. 2016.

. 2016 Feb 20;34(6):521-3.

doi: 10.1200/JCO.2015.64.7495. Epub 2016 Jan 11.

¹ Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia sherene.loi@petermac.org.
² Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

No abstract available

Comment on

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Carey LA, et al. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. J Clin Oncol. 2016. PMID: 26527775 Free PMC article. Clinical Trial.